ARWR Past Earnings image   This ARWR past earnings page last updated 8/8/2022
ARWR Past Earnings
PeriodPast Earnings DateGAAP
Q3 20228/4/2022-0.680
Q2 20225/10/20220.410
Q1 20222/2/2022-0.600
Q4 202111/22/2021-0.610
Q3 20218/5/2021-0.290
Q2 20215/4/2021-0.260
Q1 20212/4/2021-0.200
Q4 202011/23/2020-0.480
Q3 20208/5/2020-0.130
Q2 20205/7/2020-0.200
Q1 20202/5/2020-0.030
Q4 201911/25/20190.110
Q3 20198/5/20190.210
Q2 20195/8/20190.240
Q1 20192/7/20190.13
Q4 201812/11/2018-0.12
Q3 20188/7/2018-0.18
Q2 20185/8/2018-0.18
Q1 20182/9/2018-0.18
Q4 201712/12/2017-0.15
Q3 20178/3/2017-0.07
Q2 20175/3/2017-0.08
Q1 20172/6/2017-0.17
Q4 201612/14/2016-0.34
Q3 20168/9/2016-0.32
Q2 20165/10/2016-0.35
Q1 20162/9/2016-0.32
Q4 201512/14/2015-0.41
Q3 20158/4/2015-0.27
Q2 20155/11/2015-0.51
Q1 20152/9/2015-0.41
Q4 201411/25/2014-0.42
Q3 20148/12/2014-0.22
Q2 20145/6/20140.31
Q1 20144/4/20140.28
FY 201312/18/2013-1.3
Q3 20138/7/2013-0.23
Q2 20135/9/2013-0.41
Q1 20132/4/2013-0.28
Q4 201212/20/2012-0.43
ARWR Past Revenue
PeriodPast Earnings DateGAAP
Q3 20228/4/20220.03B
Q2 20225/10/20220.15B
Q1 20222/2/20220.03B
Q4 202111/22/20210.04B
Q3 20218/5/20210.05B
Q2 20215/4/20210.03B
Q1 20212/4/20210.02B
Q4 202011/23/20200.01B
Q3 20208/5/20200.03B
Q2 20205/7/20200.02B
Q1 20202/5/20200.03B
Q4 201911/25/20190.04B
Q3 20198/5/20190.04B
Q2 20195/8/20190.05B
Q1 20192/7/201934.66M
Q4 201812/11/201811.26M
Q3 20188/7/2018727375
Q2 20185/8/2018650125
Q1 20182/9/20183.51M
Q4 201712/12/20178.71M
Q3 20178/3/20179.34M
Q2 20175/3/20178.99M
Q1 20172/6/20174.37M
Q4 201612/14/201631250
Q3 20168/9/201639583
Q2 20165/10/201643750
Q1 20162/9/201643750
Q4 201512/14/201543750
Q3 20158/4/2015123750
Q2 20155/11/201543750
Q1 20152/9/2015170750
Q4 201411/25/201440000
Q3 20148/12/201440000
Q2 20145/6/201443750
Q1 20144/4/20144.60M
FY 201312/18/2013290266
Q3 20138/7/201343750
Q2 20135/9/201343750
Q1 20132/4/20130.05M
Q4 201212/20/20120.04M
Quotes delayed 20 minutes

Email EnvelopeFree ARWR Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold S&P 500 Stocks
10 Most Overbought S&P 500 Stocks
10 ETFs With Stocks Insiders Are Buying
10 ETFs With Most Upside To Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active S&P Call & Put Options
Arrowhead Pharmaceuticals (ARWR) is categorized under the Healthcare sector; to help you further research past earnings across stocks, below are some other companies in the same sector:

ASMB Past Earnings
ASRT Past Earnings
ATEC Past Earnings
ATHA Past Earnings
ATHX Past Earnings
ATNF Past Earnings
ATNX Past Earnings
ATOS Past Earnings
ATRA Past Earnings
ATRC Past Earnings

ARWR Past Earnings Q&A

What was the best and worst ARWR past earnings results?
For Arrowhead Pharmaceuticals, I'm wondering what the company's very best and worst earnings results have been, on an earnings per share basis?

✔️Accepted answer: The highest ARWR past earnings result in our data set was 0.410/share posted in Q2 2022, while the lowest was in FY 2013 when ARWR posted -1.3/share.

  Suggested answer: The biggest top line earnings performance — aka revenue — quarter was in Q2 2022 when ARWR reported 0.15B in revenue, while the quarter with the lowest revenue in our data set was Q4 2016 at 31250 of revenue.

  Suggested answer: There are 40 ARWR past earnings results in our data set.

On this page we presented the ARWR past earnings date information for Arrowhead Pharmaceuticals. Reviewing that ARWR Past Earnings for the company, we see that the highest past earnings result in our data set was in Q2 2022, when ARWR posted gaap of 0.410/share. Meanwhile the lowest ARWR past earnings result was in FY 2013, when ARWR posted gaap of -1.3/share. Turning to top line revenue performance, the biggest revenue quarter in our data set was seen in Q2 2022 when ARWR reported 0.15B in revenue, while the smallest revenue quarter was Q4 2016 when ARWR reported 31250 in revenue.

Any self directed investor doing their due diligence on ARWR or any other given stock can benefit from researching all of the Arrowhead Pharmaceuticals past earnings — and here, we present each quarter's result all together on one page for easy comparison. Studying this information can help when projecting future earnings, as well as determining whether the past earnings trajectory justifies the current stock value. That's why we bring you PastEarnings.com to make it easy for investors to investigate Arrowhead Pharmaceuticals past earnings, or the past earnings information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for ARWR. Thanks for visiting, and the next time you need to research ARWR past earnings or those of another stock, we hope you'll think of our site, as your go-to past earnings research resource of choice.

Recommended: Institutional Holders of NUSI, VTC Videos, VKTX Videos.

 

ARWR Past Earnings | www.PastEarnings.com | Copyright © 2020 - 2022, All Rights Reserved

Nothing in PastEarnings.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.